Sequential therapies for proliferative lupus nephritis.

By G. Contreras, V. Pardo, B. Leclercq, O. Lenz, E. Tozman, Patricia O'Nan, D. Roth. New England Journal of Medicine, 2004

655 citations recorded by the source corpus.

Subfields: Hepatology, Rheumatology, Transplantation

View Paper: https://www.semanticscholar.org/paper/fb9b4ac2fcc9e413555bf4e9d46fbe46b51b7cbb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Kai-Uwe Eckardt
2. B. Kasiske

In Rheumatology

1. J. Smolen
2. Kai-Uwe Eckardt
3. B. Kasiske

Citations in the corpus

• American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis (2012, methodology): “once a month for 6 doses), followed by maintenance treatment with MMF or AZA [38–40] (Level A).”
• EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (2007, methodology): “and then were randomly assigned to IV-CY, oral azathioprine or oral MMF for 1–3 years.(130) The event-free survival rate for the”
• KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, background): “pulses for 1 year beyond remission.(638) This study showed that, over 72 months, the patients treated with maintenance azathioprine or MMF were significantly less likely to reach the composite end-point of death or CKD than the cyclophosphamide maintenance group, and to experience”